+ T cells contribute to immunological protection against pathogens by purging the host of infected cells. These responses are driven by the T cells' initial encounter with presented antigen, resulting in clonal expansion and differentiation of effector and memory subsets [1] . The resulting memory T cells are characterized by their ability to persist in the absence of antigen, and, by comparison with naive T cells, they function more rapidly and proliferate more vigorously during reexposure to antigen [2] . Many criteria have been used to define antigen-experienced memory CD8 +
T cells, including the expression of homing receptors CCR7 and CD62L [3] , costimulatory molecules CD27 and CD28 [4] [5] [6] , activation molecules CD45RA and CD45RO [6, 7] , and, most recently, the cytokine receptor CD127 (interleukin [IL]-7 receptor a) [8] . The expression of CD127 allows cells to respond to IL-7, which, along with IL-15, is important for survival and homeostatic proliferation of memory T cells [9, 10] .
During chronic infections, including HIV, CD8 + T cell responses operate to contain the virus at a steadystate level. Initially, antiviral CD8 + T cells control the acute viremic phase of the infection, resulting in the establishment of the viral set point [11, 12] . Despite this initially robust immune response directed against HIV, it eventually fails, resulting in AIDS and death in the vast majority of untreated patients. Fortunately, antiretroviral therapy (ART) can control HIV to undetectable levels in the plasma, significantly abating or even reversing disease progression [13, 14] . These distinct levels of viral control present an opportunity to determine how the changing magnitude of antigen stimulation impacts the differentiation state and functional quality of CD8 + T cell subsets in humans.
The expression of CD127 on CD8 + T cells in the periphery is dynamic. Initially, naive T cells are CD127
hi . These cells down-regulate expression of this receptor as they divide and differentiate into effector cells; however, up-regulation of CD127 is associated with the emergence and survival of authentic memory T cells [8] . Initial studies demonstrated that the lack of HIV-specific cytotoxic T lymphocyte activity was associated with the loss of CD127 expression [15] . More recently, several studies determined that continuous viral replication is associated with CD127 lo expression [16, 17] , and other reports have also shown that, after viral suppression, CD127 hi cells can emerge [18] [19] [20] [21] . In addition, it has been reported that the levels of CD127 lo CD8
+ T cells expanded in HIV-infected individuals correlate with clinical markers of disease progression, including increased viral load (VL) and the decline of CD4 + T cell counts [22] . However, most of these studies did not evaluate HIV-specific responses, and those that did investigated the expression of CD127 in individuals with chronic infection not receiving ART [16, 22, 23] . The present study corroborates the data of others for the individuals with chronic infection and extends them to include the expression of CD127 on HLA class I-restricted HIV-specific peptide responses in HIV-infected individuals with early and chronic infection followed longitudinally before and after the initiation of ART. We demonstrate that an HIV-specific CD127 hi CD8
+ T cell population is maintained only in individuals treated with ART shortly after acute infection.
SUBJECTS, MATERIALS, AND METHODS
Subjects and HLA typing. Blood was collected from HIVinfected ( ) and healthy volunteers ( ) at the Unin p 26 n p 10 versity of Alabama at Birmingham (UAB) after obtaining written, informed consent, as approved by the institutional review board. HLA typing was performed at the Tissue Typing Center at UAB Hospital by use of the Micro SSP HLA Typing System (One Lamba). Of the HIV-infected volunteers, 6 were referred from the National Institutes of Health (NIH)-sponsored Multicenter Acute Infection and Early Disease Research Program (AIEDRP) cohort. All had documentation of a negative ELISA result within at least 12 months of enrollment and met the AIEDRP criteria for very recent infection, as defined by documented seroconversion within 3 months, a desensitized or detuned ELISA consistent with infection within the prior 120 days, or primary HIV-1 infection as demonstrated by high VL in the setting of negative or indeterminant HIV-1 serologic analysis. Volunteers were divided into the following groups, as outlined in T cell count. HIV RNA levels in the plasma samples were measured using the Amplicor Ultra Sensitive HIV-1 Monitor assay (version 1.5; Roche Diagnostics Systems), in accordance with the manufacturer's protocol. CD4 + T cells were measured as described elsewhere [24] .
Antigens. HLA-restricted HIV-specific responses have been previously mapped in these individuals by use of the interferon (IFN)-g enzyme-linked immunospot; thus, individual peptides (9-11mers) were used to stimulate T cell responses. These included: (1) optimized HLA-restricted HIV-1 CD8 + T cell epitopes of 9-11 aa in length, as described in the Los Alamos National Laboratory HIV Immunology Database (100 mmol/ L); (2) the CEF pool (NIH AIDS Research and Reference Reagent Program), composed of optimized HLA-restricted CD8 epitopes from cytomegalovirus (CMV), Epstein-Barr virus (EBV), and influenza virus (100 mmol/L); (3) individual optimized CMV, EBV, or influenza virus CD8 epitopes (100 mmol/ L); and (4) staphylococcal enterotoxin B (SEB) (1 mg/mL). In the few instances in which no optimized epitope was defined, a 15mer or 20mer peptide was used (20 mg/mL). All HIVspecific responses were elicited using a single peptide per stimulation. The CEF pool, consisting of 32 peptides, was used for detecting non-HIV specific responses in some volunteers.
Intracellular cytokine staining assay. Intracellular cytokine staining was performed as described elsewhere [20, 25] . Cells were pulsed with the appropriate antigen for 1 hour before monensin was added, followed by a 4-h incubation at 37ЊC in 5% CO 2 . The surface phenotype of peripheral-blood mononuclear cell (PBMC) samples was determined by staining with anti-CD3-Pacific Blue or anti-CD4 or anti-CD8-PercpCy5.5 (all from Becton Dickinson), together with anti-CD127-phycoerythrin antibodies (Beckman Coulter). For intracellular cytokine staining, we used anti-IL-2-APC, anti-tumor necrosis factor (TNF)-a-fluorescein isothiocyanate (FITC) or PeCy7, and anti-IFN-g-PeCy7 or FITC-conjugated antibodies (Becton Dickinson). At least 50,000 CD3 + events were acquired from each sample by use of an LSR II flow cytometer (Becton Dickinson). Data were analyzed using FlowJo software (version 6.3; TreeStar). Lymphocytes were analyzed on the basis of forward and side scatter profiles. CD3 + CD8 + cells were then gated to determine the expression of CD127 on cytokine-positive (IFNg, IL-2, or TNF-a) antigen-specific T cells. The positive control SEB was used to determine where to gate on CD127 lo versus CD127 hi populations, because the cytokine secretion from this control clearly delineated the 2 populations. We then applied these gates to the unstimulated controls to set gates for the negative control and used these gates for all samples from the same individual for each time point. Statistics. Statistical analyses were performed using the nonparametric Mann-Whitney U test with Analyze-It software. Differences were considered to be significant on the basis of 95% confidence intervals ( ). Interquartile ranges were P р .05 calculated using Microsoft Excel 2004.
RESULTS

Antigen-specific cytokine-secreting CD8 + T cells from healthy and HIV-infected volunteers. Although the magnitude of the HIV-specific CD8
+ T cell responses as measured by IFN-g production has inconsistently correlated with viral replication [24] , more recent studies indicate that production of cytokines, including IFN-g and IL-2, is more reliably associated with viral control [26] . To expand on these studies, we measured the mean frequency of antigen-specific responses as detected by production of IFN-g, IL-2, and/or TNF-a in 4 groups of HIV-infected patients, as described in Subjects, Materials, and Methods had decreased production of IL-2 ( and , re-P p .001 P p .02 spectively), compared with those specific for non-HIV epitopes (CEF). Moreover, responses from individuals with chronic in- + T cells ( figure 2B ) from all HIV-infected groups was significantly lower than that on cells from healthy control subjects ( ). P р .04
Antigen-specific cytokine-secreting CD127 hi T cells from healthy and HIV-infected volunteers. To refine our analyses, we sought to examine the impact that virologic control has on CD127 expression and cytokine secretion of antigen-specific CD8 + T cells. PBMCs were stimulated in vitro with non-HIV (CEF pool or single peptides from the CEF pool) and HIVderived single peptide epitopes. Representative dot plots of IFN-g production are shown in figure 3, and + T cells, which produce IFN-g after stimulation with CEF peptides or 9-15mer peptides from HIV, are shown in the upper left and right quadrants, respectively. The specific peptides used for the non-HIV antigen and the HIV antigen, respectively, in each patient group were as follows: (1) 
DISCUSSION
In the present study, we inspected the HIV-specific CD8 + T cell response in cohorts of patients with distinct durations of infection and VL. In particular, we sought to define how the generation and maintenance of memory (CD127 hi ) CD8 + T cells as well as the capacity to secrete cytokines and proliferate ex vivo were interconnected with the extent of viral control. Consistent with previous studies, our findings demonstrated an inverse correlation between HIV-specific IL-2 production by CD8 + T cells and plasma VL [28, 29] . We now expand on these studies by demonstrating that optimal HIV-specific CD8 + T cell memory (CD127 hi ) responses are generated only when they are established early during infection after control of viremia. In contrast, HIV-1-specific CD127 hi CD8 + T cells were rarely detectable in patients with chronic infection, even individuals who controlled viral replication without ART (controllers). Notably, CD127 hi CD8 + T cells specific for the controlled viral infections of EBV and CMV were fully functional by all analyses in every group studied, suggesting that when these responses developed (most likely before HIV infection), the immune system was intact and capable of generating long-term memory. Similar to our findings, several groups have demonstrated differences in total CD127 expression on CD8 + T cells in patients with HIV infection [15, 22, 30, 19] . One study showed that decreased total CD127 expression during viremic periods can be partially recovered with control of virus by ART [19] . We examined not only CD127 expression on total populations of CD8 + T cells in different patient groups but also analyzed CD127 expression on antigen-specific cells in patients who differed in terms of virologic control. During viremic states, patients with chronic HIV infection have predominately CD127 lo CD8 + T cells consistent with an effector cell phenotype. Similar to previous reports, we found that control of HIV with ART results in partial up-regulation of CD127 on the entire CD8 + T cell population ( figure 2A) . However, we demonstrate that control of viremia with ART in patients with chronic infection does not result in modulation of HIV-specific T cells to a CD127 hi memory phenotype ( figure 5A ). Instead, these antigen-specific cells persist in a CD127 lo pseudoeffector phenotype or are deleted over time. Our findings in patients with chronic infection are similar to what has recently been reported [23] ; however, we now demonstrate that these skewed CD8 + T cells are not a global phenomenon, because the same subjects have responses to non-HIV CD8 + T cell epitopes that predominantly up-regulate CD127 ( figure 4A ).
Controllers are a unique group of patients who are able to attain low plasma VL and maintain high absolute CD4 + T cells counts without ART. Examination of HIV-1-specific CD8 + T cell responses in this group demonstrated patterns of cytokine responses similar to those in acutely infected patients. Additionally, proliferative responses to ex vivo antigenic stimulation were maintained for several years after the initial diagnosis (S.L.H. and P.A.G., unpublished data). Despite these findings, HIV-1-specific CD8 + T cells as measured by IFN-g secretion were primarily CD127 lo in this controller cohort. We postulate that this effector phenotype persists because of low-level viral replication in the periphery or lymph node compartments. The phenomenon of low-level viremia, even in elite suppressors, has recently been described [30] . This low-level viremia may necessitate constant CD127 lo effector cells to contain viral replication at low levels and may not permit the emergence or maturation of CD127 hi cells. Unlike patients with chronic infection who have impaired CD4 + T cell help and are unable to up-regulate CD127 expression in aviremic settings on ART, we believe controllers likely maintain this CD8 + T cell function. Because these patients have intact CD4 + T cell help, one would reason that, if VL were further contained by ART, a memory pool of CD8 + T cells with increased expression of CD127 would emerge. Our group of controllers has been followed only for an average of 10 years (range, 4-18 years) and cannot be considered long-term nonprogressors, as described in other studies [31, 32] . As such, expression of CD127 on HIV-specific CD8 + T cells in these latter patients may not match the patterns observed in our controller cohort.
Unlike patients with chronic infection, those identified and treated early after infection had preserved polyfunctional CD8 + T cell immune responses. These individuals generated HIVspecific CD8 + T cells capable of secreting IFN-g, IL-2, and TNFa, and these responses most closely resembled those specific for non-HIV antigens (CEF) (figures 1, 3, and 4). Early during disease, HIV-specific CD8 + T cell responses were predominantly CD127 lo , consistent with the generation of effector CD8 + T cells (figures 5B and 6). Furthermore, once viral replication was artificially controlled (by ART), a dominant CD127 hi population emerged that is reminiscent of what is observed after naturally controlled viral infections. These HIV-specific CD8 + T cells were also able to proliferate, unlike those obtained from patients with chronic infection (S.L.H. and P.A.G., unpublished data). It, therefore, appears that polyfunctional HIV-1-specific CD8 + T cells can be maintained with the use of ART; however, this effect may eventually be lost with uncontrolled viral replication possibly because of progressive loss of CD4 + T cell help, which has been previously shown to be vital for optimally functioning CD8 + T cells [29, [33] [34] [35] . Additionally, it is plausible that signals provided by CD4 + T cells are necessary to generate and sustain these long-lived memory CD8 + T cells demarcated by their ability to express CD127 once antigen is cleared [36] .
In summary, polyfunctional CD8 + T cell responses with generation and maintenance of optimal memory responses are unique to patients identified and treated early after infection. Even controllers (capable of controlling viremia for years without ART) appear to have subtle defects in these responses (evidenced by an antigen-specific CD127 lo population) or require the constant presence of these effector cells (CD127 lo ) to control low-level virus replication. HIV-specific CD8 + T cell responses may be best preserved by administering ART to lower VL at a time when CD4 + T cell help is present. Moreover, these patients would likely gain the most benefit from therapeutic vaccinations, given that the ability of CD8 + T cells to attain a memory phenotype appears to be unimpaired and the progressive defects observed in their counterparts with chronic infection have not ensued. Continued research into the mechanism of skewed CD8 + T cell responses is needed to determine whether support via CD4 + T cell help or cytokine treatment can recover polyfunctional CD8 + T cell memory responses in patients with chronic infection.
